Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
|
+$465M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$268M |
| 3 |
Verizon
VZ
|
+$239M |
| 4 |
Microsoft
MSFT
|
+$212M |
| 5 |
Apple
AAPL
|
+$201M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
|
+$421M |
| 2 |
Becton Dickinson
BDX
|
+$213M |
| 3 |
Home Depot
HD
|
+$191M |
| 4 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$132M |
| 5 |
Broadcom
AVGO
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.96% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.98% |
| 4 | Consumer Discretionary | 10.85% |
| 5 | Industrials | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Stagwell
STGW
$2.07B
| $1.38M | ﹤0.01% |
158,543
+3,697
| +2% | +$31.8K |
|
2802
iShares Core Universal USD Bond ETF
IUSB
$42.9B
| $1.36M | ﹤0.01% |
+26,072
| New | +$1.38M |
|
2803
Qiagen
QGEN
$8.54B
| $1.35M | ﹤0.01% |
22,954
+1,202
| +6% | +$68.9K |
|
2804
Ocular Therapeutix
OCUL
$1.79B
| $1.35M | ﹤0.01% |
193,093
-57,748
| -23% | -$448K |
|
2805
Hackett Group
HCKT
$270M
| $1.34M | ﹤0.01% |
65,269
+1,578
| +2% | +$33.1K |
|
2806
Rayonier Advanced Materials
RYAM
$604M
| $1.33M | ﹤0.01% |
232,705
+4,528
| +2% | +$29.4K |
|
2807
Sight Sciences
SGHT
$286M
| $1.33M | ﹤0.01% |
75,522
+942
| +1% | +$20.7K |
|
2808
Lyell Immunopharma
LYEL
$317M
| $1.33M | ﹤0.01% |
8,560
+247
| +3% | +$55.1K |
|
2809
ANI Pharmaceuticals
ANIP
$1.8B
| $1.32M | ﹤0.01% |
28,605
+4,165
| +17% | +$179K |
|
2810
Digimarc Corp
DMRC
$147M
| $1.32M | ﹤0.01% |
33,388
| – | – |
|
2811
UFP Technologies
UFPT
$1.97B
| $1.32M | ﹤0.01% |
18,751
+1,489
| +9% | +$98.7K |
|
|
HAYN
2812
DELISTED
Haynes International, Inc.
HAYN
| $1.32M | ﹤0.01% |
32,619
+860
| +3% | +$34.9K |
|
2813
Centrus Energy
LEU
$3.48B
| $1.31M | ﹤0.01% |
26,175
+502
| +2% | +$28K |
|
|
LBC
2814
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $1.3M | ﹤0.01% |
92,743
+6,003
| +7% | +$84.1K |
|
|
MMAT
2815
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $1.3M | ﹤0.01% |
5,279
-273
| -5% | -$113K |
|
2816
Radiant Logistics
RLGT
$386M
| $1.3M | ﹤0.01% |
177,788
| – | – |
|
2817
Vuzix
VUZI
$194M
| $1.29M | ﹤0.01% |
149,050
+2,719
| +2% | +$29.4K |
|
2818
HCI Group
HCI
$2.23B
| $1.29M | ﹤0.01% |
15,456
+1,055
| +7% | +$123K |
|
2819
American Vanguard Corp
AVD
$68.4M
| $1.29M | ﹤0.01% |
78,708
+6,521
| +9% | +$102K |
|
2820
West Bancorporation
WTBA
$478M
| $1.29M | ﹤0.01% |
41,416
+1,056
| +3% | +$33.3K |
|
|
DAWN
2821
DELISTED
Day One Biopharmaceuticals
DAWN
| $1.28M | ﹤0.01% |
76,168
+942
| +1% | +$19.4K |
|
|
XXII
2822
22nd Century Group
XXII
$1.38M
| – | – |
0
| – | – |
|
2823
Tilly's
TLYS
$116M
| $1.28M | ﹤0.01% |
79,473
+22,220
| +39% | +$335K |
|
2824
Coastal Financial
CCB
$626M
| $1.28M | ﹤0.01% |
25,234
| – | – |
|
|
HGEN
2825
DELISTED
HUMANIGEN, INC.
HGEN
| $1.28M | ﹤0.01% |
342,910
+24,993
| +8% | +$146K |
|
Similar funds
Charles Schwab's Q4 2021 Portfolio in Review
As of Q4 2021, Charles Schwab held 3,647 positions worth $339B, up 11% from $306B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Charles Schwab's Q4 2021 filing shows 148 new, 2,572 increased, 501 reduced and 58 closed positions. Its largest new stake was Kyndryl: 2,951,149 shares worth $53.4M. The largest sale was State Street SPDR Portfolio Intermediate Term Corporate Bond ETF, an estimated $421M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q4 2021 buy was Kyndryl: 2,951,149 shares worth $53.4M.
- Charles Schwab added most to State Street SPDR Portfolio Short Term Treasury ETF in Q4 2021, an estimated $465M increase.
- Charles Schwab's biggest Q4 2021 reduction was State Street SPDR Portfolio Intermediate Term Corporate Bond ETF, cutting an estimated $421M.
- Charles Schwab fully exited Kansas City Southern in Q4 2021, selling an estimated $113M.
- Charles Schwab's ten largest holdings make up 18% of its $339B portfolio in Q4 2021.
- Charles Schwab opened 148 new positions and closed 58 in Q4 2021.
- Charles Schwab's portfolio value rose 11% quarter-over-quarter to $339B.
Based on Charles Schwab's 13F filing for Q4 2021, filed 11 Feb 2022.